Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Proxygen
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
Biotheryx will deploy its PRODEGY platform to discover candidates against novel cancer targets selected by Incyte. The deal occurred the same day as a Merck/Proxygen protein-degradation alliance.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.